Evidence map›Paper›PMID 38286936›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

Combined whole-body dynamic and static PET/CT with low-dose [

Christos Sachpekidis, Leyun Pan, Martin Groezinger, Dimitrios Stefanos Strauss, Antonia Dimitrakopoulou-Strauss

Open access · hybridAbstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Clinical performance of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Mitigating bladder signal inEJNMMI physics · 2026
    Article
  5. Article
  6. Article
  7. EJNMMI physics · 2025
    Article
  8. Review
  9. Evaluating image-derived input functions for cerebral [Frontiers in nuclear medicine · 2025
    Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Christos SachpekidisClinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69210, Heidelberg, Germany. christos_saxpe@yahoo.gr.ORCID 0000-0001-8739-8741
Leyun PanClinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69210, Heidelberg, Germany.
Martin GroezingerClinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69210, Heidelberg, Germany.
Dimitrios Stefanos StraussDepartment of Diagnostic and Interventional Radiology (DIR), Heidelberg University Hospital, Heidelberg, Germany.
Antonia Dimitrakopoulou-StraussClinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69210, Heidelberg, Germany.
German Cancer Research Center · DEHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimIn addition to significant improvements in sensitivity and image quality, the recent introduction of long axial field-of-view (LAFOV) PET/CT scanners has enabled dynamic whole-body imaging for the first time. We aim herein to determine an appropriate acquisition time range for static low-dose [ METHODOLOGY: In total, 38 prostate cancer patients were enrolled in the analysis for staging or re-staging purposes. Thirty-four patients underwent dynamic whole-body PET/CT (60 min) followed by static whole-body PET/CT and four patients underwent static whole-body PET/CT only. The activity applied was 2 MBq/kg [

resultsAnalysis of lesion detection rate showed no significant differences when reducing PET acquisitions from 10 up to 5 min. In particular, a total of 169 lesions were counted with PET-10, and the corresponding lesion detection rates (95% CI for the 90% quantile of the differences in tumor lesions) for shorter acquisitions were 100% (169/169) for PET-8 (95% CI: 0-0), 98.8% (167/169) for PET-6 (95% CI: 0-1), 95.9% (162/169) for PET-5 (95% CI: 0-3), 91.7% (155/169) for PET-4 (95% CI: 1-2), and 85.2% (144/169) for PET-2 (95% CI: 1-6). With the exception of PET-2, the differences observed between PET-10 and the other shorter acquisition protocols would have no impact on any patient in terms of clinical management. Objective evaluation of PET/CT image quality showed no significant decrease in tumor-to-background ratio (TBR) with shorter acquisition times, despite a gradual decrease in signal-to-noise ratio (SNR) in the spleen. Whole-body quantitative [

conclusionsIn prostate cancer, low-dose (2 MBq/kg) [

Indexed as

Positron Emission Tomography Computed TomographyProstatic NeoplasmsWhole Body ImagingAgedAged, 80 and overFluorine RadioisotopesHumansMaleMiddle AgedNiacinamideOligopeptidesRadiation DosageRadiopharmaceuticalsFluorine-18Fluorine RadioisotopesNiacinamideOligopeptidesPSMA-1007Radiopharmaceuticals[18F]PSMA-1007Dynamic PETKinetic modelingLAFOV PET/CTProstate cancerWhole-body PET/CT

Identifiers

PMID38286936
PMCPMC11139746
OpenAlexW4391328227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.